Fuji completes cell culture manufacturing expansion in U.K.

Fujifilm Diosynth Biotechnologies in Texas
Fujifilm Diosynth Biotechnologies has completed a 10,000-square-foot expansion of its cell culture manufacturing facility in the U.K.

In April, Fujifilm Diosynth Biotechnologies outlined $130 million in projects it had undertaken to build up a biologics CMO business, and this week it said one of those projects is ready.

The Japanese company has opened its $9 million, 10,000-square-foot, cell culture process development laboratories in Billingham, U.K., which will support its monoclonal antibody (mAb) platform for cell culture development work.

RELATED: Fujifilm invests $116M in U.S. as it races competitors for biologics contract work

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The company this spring completed a $93 million Texas manufacturing facility it picked up several years ago in its buyout of College Station, Texas-based Kalon Biotherapeutics. Kalon's facilities include high containment manufacturing and a cell culture capacity of 6,000 liters that can be expanded to 24,000 liters in upstream capacity.  

Fuji in April said that it intended to invest another $23 million to expand the Texas manufacturing facility. 

All of this is with the goal of hitting about $1 billion in biologics contract work by 2023 as Fuji races competitors to capture the burgeoning biologics CDMO business.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.